AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16452331 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplementation
Number of subjects: 327
Study 15291857 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased biopsy cores (8, 10, 12, 14 cores based on prostate volume)
Number of subjects: 132
Study 15291857 — intervention group
Group type: COMPARATOR
Intervention: Sextant biopsy (standard 6 cores)
Number of subjects: 132
Study 15291857 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased biopsy cores
Number of subjects: 132
Study 10828670 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 95
Study 10828670 — intervention group
Group type: COMPARATOR
Intervention: TUVP
Number of subjects: 95
Study 10828670 — intervention group
Group type: COMPARATOR
Intervention: VLAP
Number of subjects: 95
Study 10828670 — intervention group
Group type: COMPARATOR
Intervention: HIFU
Number of subjects: 95
Study 10828670 — intervention group
Group type: COMPARATOR
Intervention: TUNA
Number of subjects: 95
Study 8650418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebuliser (DP100)
Number of subjects: 4
Study 8650418 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic nebuliser (Pari LL)
Number of subjects: 4
Study 8650418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nebulisers
Number of subjects: 4
Study 1628135 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GM‐CSF (rhGM‐CSF) after allogeneic bone marrow transplantation
Number of subjects: 20
Study 1628135 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 20
Study 6385229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 11
Study 6385229 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine/steroids
Number of subjects: 11
Study 30762467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular split-virion quadrivalent inactivated influenza vaccine (IIV4; Fluzone® Quadrivalent)
Number of subjects: 100
Study 27898234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor (400 mg/250 mg every 12 h)
Number of subjects: 126
Study 27898234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 25417892 — intervention group
Group type: EXPERIMENTAL
Intervention: de novo CRT-D (CRT with ICD) implant
Number of subjects: 1346
Study 25417892 — intervention group
Group type: EXPERIMENTAL
Intervention: study upgrade to CRT-D
Number of subjects: 1346
Study 25417892 — intervention group
Group type: EXPERIMENTAL
Intervention: substudy CRT attempts
Number of subjects: 1346
Study 23534952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg∙kg(‐1) phenylephrine
Number of subjects: 22
Study 23534952 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 22
Study 21570352 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based regimen (T-ET): three cycles of docetaxel 100 mg/m² followed by three cycles of intravenous epirubicin 90 mg/m² and docetaxel 75 mg/m².
Number of subjects: 1856
Study 21570352 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline regimen (FEC): six cycles of intravenous fluorouracil 500 mg/m², epirubicin 100 mg/m², and cyclophosphamide 500 mg/m² or fluorouracil 600 mg/m², epirubicin 75 mg/m², cyclophosphamide 900 mg/m².
Number of subjects: 1856
Study 21570352 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall for all patients, irrespective of TP53 status.
Number of subjects: 1856
Study 21570352 — intervention group
Group type: COMPARATOR
Intervention: Taxane-based regimen (T-ET) and Anthracycline regimen (FEC) adverse events.
Number of subjects: 1856
Study 19225525 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human superoxide dismutase (rhSOD)
Number of subjects: 0
Study 19225525 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 17142706 — intervention group
Group type: EXPERIMENTAL
Intervention: MR venography with true fast imaging with steady-state precession (FISP)
Number of subjects: 24
Study 17142706 — intervention group
Group type: COMPARATOR
Intervention: Contrast agent-enhanced venography
Number of subjects: 24
Study 12750069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 15
Study 12750069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10620550 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-coated (VE) dialyzer
Number of subjects: 21
Study 10620550 — intervention group
Group type: COMPARATOR
Intervention: Synthetic polyamide (PA) dialyzer
Number of subjects: 21
Study 8811519 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-dense milk (5.0 kJ/ml with a protein-energy ratio of 11.0)
Number of subjects: 23
Study 8811519 — intervention group
Group type: COMPARATOR
Intervention: Control milk formula (2.5 kJ/ml with a protein-energy ratio of 11.0)
Number of subjects: 23
Study 1393487 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult screening test
Number of subjects: 111
Study 1393487 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult screening test for sigmoid and descending colon cancers
Number of subjects: 111
Study 1393487 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult screening test for rectal cancers
Number of subjects: 111
Study 1393487 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult screening test for right-sided cancers
Number of subjects: 111
Study 1393487 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult screening test completed over 6 days
Number of subjects: 111
Study 1393487 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult screening test completed over 3 days
Number of subjects: 111
Study 1393487 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cancers in the Haemoccult group
Number of subjects: 111
Study 3866069 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple occlusal adjustment
Number of subjects: 22
Study 3866069 — intervention group
Group type: COMPARATOR
Intervention: Mock adjustment (placebo)
Number of subjects: 22
Study 3866069 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (including those from both groups)
Number of subjects: 22
Study 31103781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hokkien caregiving
Number of subjects: 0
Study 31103781 — intervention group
Group type: COMPARATOR
Intervention: English-only caregiving (Control)
Number of subjects: 0
Study 30466489 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 3897
Study 27249005 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U BoNT‐A injection into the detrusor every six months
Number of subjects: 20
Study 25061252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Pressure Therapy (OPT) device
Number of subjects: 19
Study 22777041 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 400 mg
Number of subjects: 0
Study 22777041 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 600 mg
Number of subjects: 0
Study 22777041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22777041 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 400 mg and 600 mg
Number of subjects: 0
Study 19416278 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator self-aligning attachment system
Number of subjects: 60
Study 19416278 — intervention group
Group type: EXPERIMENTAL
Intervention: TG-O-Ring attachment system
Number of subjects: 60
Study 19416278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dal-Ro abutment
Number of subjects: 60
Study 19416278 — intervention group
Group type: COMPARATOR
Intervention: All systems
Number of subjects: 60
Study 18042519 — intervention group
Group type: EXPERIMENTAL
Intervention: PSPLs diet (200 g PSPLs/d; weeks 2, 3)
Number of subjects: 15
Study 18042519 — intervention group
Group type: COMPARATOR
Intervention: Control diet (weeks 6 and 7)
Number of subjects: 15
Study 16118310 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective Eyewear Promotion (PEP) project
Number of subjects: 0
Study 16118310 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 0
Study 11821457 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg orally once daily for 6 weeks
Number of subjects: 12
Study 11821457 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg orally once daily for 6 weeks
Number of subjects: 12
Study 11821457 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Anastrozole and Letrozole
Number of subjects: 12
Study 10348967 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous antioxidants, primarily vitamin E
Number of subjects: 0
Study 10348967 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of antioxidants
Number of subjects: 0
Study 7548700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantel‐Haenszel mean score statistic
Number of subjects: 0
Study 7548700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean score test
Number of subjects: 0
Study 7548700 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted average of the center‐specific mean differences
Number of subjects: 0
Study 7548700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed‐effects analysis of variance estimator
Number of subjects: 0
Study 1911657 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) ointment and placebo drops (AP)
Number of subjects: 97
Study 1911657 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment with steroid drops (PS)
Number of subjects: 97
Study 1911657 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir ointment with steroid drops (AS)
Number of subjects: 97
Study 6783231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline
Number of subjects: 18
Study 6783231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30039978 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen
Number of subjects: 21105
Study 30039978 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose edoxaban regimen
Number of subjects: 21105
Study 27757774 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 7-factor model
Number of subjects: 663
Study 27757774 — intervention group
Group type: COMPARATOR
Intervention: 5-factor model
Number of subjects: 663
Study 27757774 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal consistency
Number of subjects: 663
Study 27757774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceiling effects
Number of subjects: 663
Study 26358968 — intervention group
Group type: EXPERIMENTAL
Intervention: iRDT (BD Directigen A + B)
Number of subjects: 100
Study 26358968 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study 23549690 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobic exercises at different intensities in aquatic environment
Number of subjects: 15
Study 23549690 — intervention group
Group type: COMPARATOR
Intervention: Water aerobic exercises at different intensities in dry land environment
Number of subjects: 15
Study 23549690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross country skiing in aquatic environment
Number of subjects: 15
Study 20303230 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills course (7-hour course using AFLS methodology)
Number of subjects: 33
Study 20303230 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 19774423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational reminder
Number of subjects: 775
Study 19774423 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 775
Study 17597952 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer tutor review sessions
Number of subjects: 51
Study 17597952 — intervention group
Group type: COMPARATOR
Intervention: Approved Clinical Instructor review sessions
Number of subjects: 51
Study 15149421 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental ostial PV isolation
Number of subjects: 40
Study 15149421 — intervention group
Group type: COMPARATOR
Intervention: Circumferential extra-ostial PV isolation
Number of subjects: 40
Study 15149421 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 11546902 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dextroamphetamine
Number of subjects: 21
Study 11546902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9039254 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic NCPAP titration (Horizon, DeVilbiss)
Number of subjects: 122
Study 9039254 — intervention group
Group type: COMPARATOR
Intervention: Manual NCPAP titration
Number of subjects: 122
Study 7960016 — intervention group
Group type: EXPERIMENTAL
Intervention: High cardiorespiratory fitness (VO2peak 46.6 +/- 6.5 mL.kg-1.min-1)
Number of subjects: 31
Study 7960016 — intervention group
Group type: COMPARATOR
Intervention: Moderate cardiorespiratory fitness (VO2peak 35.9 +/- 1.9 mL.kg-1.min-1)
Number of subjects: 31
Study 7960016 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (1217.7 +/- 98.4 J.kg-1.wk-1)
Number of subjects: 31
Study 7960016 — intervention group
Group type: COMPARATOR
Intervention: Moderate physical activity (1015.5 +/- 49.4 J.kg-1.wk-1)
Number of subjects: 31
Study 3236323 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily nitrendipine (20 mg)
Number of subjects: 19
Study 3236323 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily nitrendipine (20 mg)
Number of subjects: 19
Study 3236323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31749028 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx intervention
Number of subjects: 374
Study 30475968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet rich in olive oil (MedDiet)
Number of subjects: 241
Study 30475968 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 241
Study 28658562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Infant Psychoanalysis (MIP)
Number of subjects: 10
Study 28658562 — intervention group
Group type: COMPARATOR
Intervention: Standard child health center care
Number of subjects: 10
Study 25742730 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir 500/100 mg BID on days 1-7 and 1000/100 mg BID on days 8-14
Number of subjects: 23
Study 25742730 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir regimen
Number of subjects: 23
Study 25742730 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified saquinavir/ritonavir regimen
Number of subjects: 23
Study 23937034 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive PHILOS fixation combined with injectable bone
Number of subjects: 80
Study 23937034 — intervention group
Group type: COMPARATOR
Intervention: PHILOS fixation
Number of subjects: 80
Study 20463104 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA vaccine (intradermally or intramuscularly) with GM-CSF adjuvant, boosted with modified vaccinia virus Ankara (HIV-MVA) at 9 months
Number of subjects: 38
Study 18208743 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed with polyglycolic mesh (Group B)
Number of subjects: 143
Study 18208743 — intervention group
Group type: COMPARATOR
Intervention: Simple closed laparotomy (Group A)
Number of subjects: 143
Study 16882101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun ginseng (SG) 3000 mg a day
Number of subjects: 53
Study 16882101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 14696886 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia with preservative-free bupivacaine hydrochloride 0.5%
Number of subjects: 200
Study 14696886 — intervention group
Group type: COMPARATOR
Intervention: Intracameral anesthesia with preservative-free bupivacaine hydrochloride 0.5%
Number of subjects: 200
Study 10534036 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of intravenous methyl prednisolone administered prehospital to asthma patients (11 patients in year 2)
Number of subjects: 219
Study 10534036 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not receive prehospital steroids)
Number of subjects: 219
Study 8704017 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium chain triglycerides and long chain triglycerides (MCT/LCT) in a ratio of 1:1
Number of subjects: 0
Study 8704017 — intervention group
Group type: COMPARATOR
Intervention: Long chain triglycerides (LCT)
Number of subjects: 0
Study 1888422 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane‐N2O/O2‐anaesthesia
Number of subjects: 40
Study 1888422 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane‐N2O/O2‐anaesthesia
Number of subjects: 40
Study 1888422 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam‐fentanyl‐N2O/O2‐anaesthesia
Number of subjects: 40
Study 1888422 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam‐ketamine‐N2O/O2‐anaesthesia
Number of subjects: 40
Study 1888422 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol‐N2O/O2‐anaesthesia
Number of subjects: 40
Study 6353878 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg clonidine at 8 a.m. and 0.15 mg at 10 p.m.
Number of subjects: 10
Study 4064110 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial sheath
Number of subjects: 184
Study 4064110 — intervention group
Group type: COMPARATOR
Intervention: Standard Seldinger technique (Control)
Number of subjects: 184
Study 29846794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise training (CRAE) for 12 weeks, 5 times per week, intensity increased from 40 to 70% HRR
Number of subjects: 40
Study 29846794 — intervention group
Group type: COMPARATOR
Intervention: No exercise (CON)
Number of subjects: 40
Study 27876029 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) system
Number of subjects: 334
Study 27876029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 334
Study 24742226 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzu scent inhalation
Number of subjects: 20
Study 24742226 — intervention group
Group type: COMPARATOR
Intervention: Unscented water (control)
Number of subjects: 20
Study 22985564 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 198
Study 22985564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogue (NA) treatment
Number of subjects: 198
Study 22985564 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 198
Study 22985564 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-negative group
Number of subjects: 198
Study 22985564 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-positive group
Number of subjects: 198
Study 20504358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dimensional and multi-professional educational senior meetings
Number of subjects: 450
Study 20504358 — intervention group
Group type: COMPARATOR
Intervention: Preventive home visits
Number of subjects: 450
Study 18672991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 30
Study 18672991 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no intervention
Number of subjects: 30
Study 16393755 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel search
Number of subjects: 31
Study 16393755 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial search
Number of subjects: 31
Study 16393755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low performing patients
Number of subjects: 31
Study 16393755 — intervention group
Group type: EXPERIMENTAL
Intervention: LH MCA strokes
Number of subjects: 31
Study 16393755 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired rightward shifting
Number of subjects: 31
Study 12891074 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple nucleoside regimen (Trizivir)
Number of subjects: 40
Study 12891074 — intervention group
Group type: COMPARATOR
Intervention: NNRTI-containing regimen (baseline therapy)
Number of subjects: 40
Study 10501818 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg per day
Number of subjects: 197
Study 10501818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg per day
Number of subjects: 197
Study 10501818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg per day
Number of subjects: 197
Study 10501818 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg per day
Number of subjects: 197
Study 10501818 — intervention group
Group type: EXPERIMENTAL
Intervention: All statins
Number of subjects: 197
Study 9375153 — intervention group
Group type: EXPERIMENTAL
Intervention: Late posttraumatic seizures (occurring 8 or more days posttrauma)
Number of subjects: 210
Study 9375153 — intervention group
Group type: EXPERIMENTAL
Intervention: Head injured patients with late posttraumatic seizures
Number of subjects: 210
Study 9375153 — intervention group
Group type: EXPERIMENTAL
Intervention: Head injured patients with late posttraumatic seizures (after controlling for head injury severity)
Number of subjects: 210
Study 9375153 — intervention group
Group type: COMPARATOR
Intervention: Patients who remained seizure free
Number of subjects: 210
Study 2006656 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 742
Study 2006656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 6802411 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory percussion
Number of subjects: 89
Study 6802411 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonoscopy
Number of subjects: 89
Study 31910385 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-RCTs
Number of subjects: 21
Study 31910385 — intervention group
Group type: COMPARATOR
Intervention: RCTs
Number of subjects: 21
Study 31362776 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO2R) added to non-invasive ventilation (NIV)
Number of subjects: 24
Study 31362776 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV) alone
Number of subjects: 24
Study 31362776 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO2R and/or NIV
Number of subjects: 24
Study 31362776 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO2R and NIV
Number of subjects: 24
Study 30092844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0Phobia (gamified self-guided VRET delivered through a smartphone app)
Number of subjects: 180